Oral mucositis is a nearly inevitable complication for patients undergoing chemotherapy or radiation treatment for head or neck cancer.
FDA Approves First Maintenance Therapy Drug for Lung Cancer
Two pharmaceutical companies are eager to advance a different approach to treating lung cancer.
CBCE Launches Continuing Education App for iPhone
The new app allows for fully accredited multimedia CME content such as treatment updates, conference highlights, and tests.
Positive Peer Review for Aureon’s Prostate Px+
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
CombinatoRx to Merge with Neuromed
CombinatoRx has signed an all-stock merger agreement with Neuromed.
Aureon Featured In TV Segment
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient Files Registration Agreement With SEC
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
Promising Genetic Biomarker Identified for Colorectal Cancer
A new genetic discovery could lead to easier detection of colorectal cancer.
